Liposomal Sustained-Release Delivery Systems for Intravenous Injection. III. : Antitumor Activity of Lipophilic Mitomycin C Prodrug-Bearing Liposomes

スポンサーリンク

概要

• 論文の詳細を見る

• An intravenously injectable sustained-release delivery system for mitomycin C (MMC) was prepared by formulating a lipophilic MMC prodrug, N-(cholesteryloxycarbonyl)glycyl MMC (COCG-MMC), in unilamellar liposomes, and its blood disposition and antitumor activity were investigated in mice. Liposomes composed of egg phosphatidylcholine, egg sphingomyelin and COCG-MMC in a molar ratio of 7 : 3 : X (X=0-2.7) were prepared by the combination of controlled dialysis or sonication and sequential extrusion. All the preparations prepared by controlled dialysis showed a fairly narrow size distribution. After intavenous injection of COCG-MMC-bearing liposomes at a dose of 20 μmol/kg as a prodrug, the blood levels of regenerated MMC were maintained for the first 7 h in the range of 1.16 to 0.48 μM. In contrast, when an equimolar amount of MMC was given in an aqueous solution, MMC was rapidly cleared with little remaining in the circulation after 2 h. COCG-MMC exhibited significant cytotoxicity against P 388 leukemia in vitro and its activity was approximately one-third that of the parent drug. Prodrug-bearing liposomes inhibited the growth of subcutaneously-implanted Colon 26 adenocarcinoma and human mammary carcinoma MX-1 xenograft. Compared with MMC aqueous solution, prodrug-bearing liposomes showed reduced antitumor activity and reduced toxicity. In each tumor system, the body weight change differences (test minus controls), indices of host toxicity, at the ID_<50>'s (the doses which inhibit tumor growth to 50% of controls) showed no significant difference between these dosage forms. The results indicate that COCG-MMC-bearing liposomes successully maintain blood MMC levels over a prolonged period of time, but their therapeutic efficacy is almost equal to that of MMC aqueous solution.

• 社団法人日本薬学会の論文
• 1988-09-25

著者

• 藤崎 二朗

  Exploratory Research Laboratories Fujisawa Pharmaceutical Company Ltd.

• 藤崎 二郎

  藤沢薬品工業探索研究所

• 藤崎 二郎

  藤沢薬品工業

• 徳永 雄二

  Exploratory Research Laboratories, Fujisawa Pharmaceutical Company, Ltd.,

• 岩佐 知明

  Exploratory Research Laboratories, Fujisawa Pharmaceutical Company, Ltd.,

• 沢居 清治

  Exploratory Research Laboratories, Fujisawa Pharmaceutical Company, Ltd.,

• 加賀山 彰

  Exploratory Research Laboratories, Fujisawa Pharmaceutical Company, Ltd.,

• 藤崎 二郎

  Exploratory Research Laboratories, Fujisawa Pharmaceutical Company, Ltd.,

• 加賀山 影

  Exploratory Research Laboratories, Fujisawa Pharmaceutical Company, Ltd.,

• 徳永 雄二

  Pharmaceutical Institute, Tohoku University

• 徳永 雄二

  藤沢薬品工業 開発第二研

• 沢居 清治

  Exploratory Research Laboratories Fujisawa Pharmaceutical Company Ltd.

• 加賀山 彰

  Exploratory Research Laboratories Fujisawa Pharmaceutical Company Ltd.

• 岩佐 知明

  Exploratory Research Laboratories Fujisawa Pharmaceutical Company Ltd.

関連論文

• Regional Capacities of Gastrointestinal Absorption and Lymphatic Transport for Lipid-Soluble Dyes in Rats
• Potential Absorption of Heparin from the Small Intestine and the Large Intestine in the Presence of Monoolein Mixed Micelles
• キット製剤の将来展望(E・薬剤学, 製剤学, 病院薬学)
• Liposomal Sustained-Release Delivary Systems for Instravenous Injection. V. : Biological Disposition of Liposome-Entrapped Lipophilic Prodrug of 1-β-D-Arabinofuranosylcytosine
• Liposomal Sustained-Release Delivery Systems for Intravenous Injection. IV. : Antitumor Activity of Newly Synthesized Lipophilic 1-β-D-Arabinofuranosylcytosine Prodrug-Bearing Liposomes
• Liposomal Sustained-Release Delivery Systems for Intravenous Injection. III. : Antitumor Activity of Lipophilic Mitomycin C Prodrug-Bearing Liposomes
• Liposomal Sustained-Release Delivery Systems for Intravenous Injection. II. : Design of Liposome Carriers and Blood Disposition of Lipophilic Mitomycin C Prodrug-Bearing Liposomes
• Liposomal Sustained-Release Delivery Systems for Intravenous Injection. I. : Physicochemical and Biological Properties of Newly Synthesized Lipophilic Derivatives of Mitomycin C
• INDIRECT ELECTROREDUCTIVE CYCLIZATION FOR SYNTHESES OF KEY INTERMEDIATES OF SEVERAL INDOLE AND IPECAC ALKALOIDS
• Effect of Some Ionic and Nonionic Surfactants on the Intramuscular Absorption of Isonicotinamide
• O-66 セファメジンαノンバイアルキットの製剤設計 (2) : 製剤特性と機能性評価
• O-65 セファメジンαノンバイアルキットの製剤設計 (1) : 設計コンセプトと有用性評価
• 放出開始時間制御型経口投与システム (TES) の設計
• Development of a Novel Drug Release System, Time-Controlled Explosion System (TES). III. Relation between Lag Time and Membrane
• セファメジンαノンバイアルキットの容器設計と品質保証
• Development of a Novel Drug Release System, Time-Controlled Explosion System (TES). II. Design of Multiparticulate TES and in Vitro Drug Release Properties
• Biopharmaceutical Study of the Hepato-biliary Transport of Drugs. IV. Development of the Method to Investigate the Process of the Active Secretion of Drugs from the Hepatocytes into the Bile Canaliculi and Its Application to the Biliary Excretion of Organ

もっと見る 閉じる

スポンサーリンク